BioSpace News Archive

Acer Therapeutics Inc. announced it has entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced plans to host a conference call and live audio webcast on Thursday, May 7, 2020 at 1:30 pm PT / 4:30 pm ET.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, provided a business update and announced financial results for the first quarter ended March 31, 2020.

Novan, Inc. announced that the Company has received meeting minutes from the April 1, 2020 Type C meeting with the U.S. Food and Drug Administration regarding SB206 for the treatment of molluscum contagiosum.

Natus Medical Incorporated, a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced financial results for the three months ended March 31, 2020.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, reported financial results for the quarter ended March 31, 2020.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has posted its Annual Report prepared in accordance with IFRS accounting standards for the year ended December 31, 2019 on its website. This report, which is only for statutory purposes, can be accessed on QIAGEN’s website at: https://corporate.qiagen.com/investor-relations/financial-reports/other-reports QIAGEN N.V. further announc

Nines Makes AI to Detect Emergent Conditions Available Free To Customers Including Those Overwhelmed By COVID-19 Diagnostics

BioSig Technologies, Inc. announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro”, was submitted to an online peer-reviewed life sciences journal.

Pluristem Therapeutics Inc. provided a summary of an Investor & Analyst Call conducted on April 30, 2020, in conjunction with the European Investment Bank and kENUP Foundation.